Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal ...( - Zingo Demonstrates Quick Effecti...),Health

- Zingo Demonstrates Quick, Effective Analgesia for Peripheral Venous

Access Procedures in Children Three to 18 Years of Age -(1)

SOUTH SAN FRANCISCO, Calif., May 5 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) announced today the publication of data in Pediatrics, the journal of the American Academy of Pediatrics, from a Phase 3 trial of Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection, the company's fast-acting, topical, needle-free local anesthetic, that showed treatment with Zingo was associated with significantly less pain during intravenous (IV) line placement or venipuncture as compared to sham placebo.(1) The study is the largest trial published to date on local anesthetic use for peripheral venous access procedures in children.

"Increased use of topical local anesthetics has long been urged to reduce peripheral venous access pain in children, but use of those tools has been limited by slow onset of action," said William T. Zempsky, M.D., Associate Professor, Department of Pediatrics, University of Connecticut; Associate Director, Pain Relief Program, Connecticut Children's Medical Center, Hartford, who led the pediatric clinical trials of Zingo. "As demonstrated in the Phase 3 trial, Zingo's rapid action is a leap forward in the control of peripheral venous access pain management for children."

More than 18 million children undergo venous access procedures, including blood draws and IV insertions, in U.S. hospitals each year.(2) In addition to the commonality of venous access procedures, they are also a source of pain for children.(3) According to a study published in the journal Pediatric Nursing, IV insertions and blood draws are the most frequently reported pai
'/>"/>